Archive for the ‘Biotechnology’ category

DGAP-News: Cytos Biotechnology Ltd: Convertible bond restructuring proposal approved by the Higher Court of the Canton …

February 6th, 2012

EquityStory AG-News: Cytos Biotechnology AG / Key word(s):MiscellaneousCytos Biotechnology Ltd: Convertible bond restructuring proposalapproved by the Higher Court of the Canton of Zurich. Strategicsolutions are further being pursued.06.02.2012 / …

Read more here:
DGAP-News: Cytos Biotechnology Ltd: Convertible bond restructuring proposal approved by the Higher Court of the Canton …

Feed 8 Billion – a Panel Discussion on Biotechnology in Agriculture part 1 – Video

February 6th, 2012


03-02-2012 22:01 Within the next two decades the population of the world is expected to climb to 8 billion people. Feed 8 Billion is a panel discussion where internationally recognized scientists address the possibility of biotechnology feeding the future population of the world. The event was co-sponsored by the Arizona State University Biotechnology Club and Campus Student Sustainability Initiatives. Moderator – Dr Jason Robert Panelists: Dr Charles Arntzen Dr Roberto Gaxiola Dr Ben Hurlbut Marci Baranski Dr Rolf Halden 7 PM, February 2nd 2012, ASU room BAC 116

Read more from the original source:
Feed 8 Billion – a Panel Discussion on Biotechnology in Agriculture part 1 – Video

New technology licensed by Pain Therapeutics for treating hemophilia

February 5th, 2012

Do you know that Hemophilia is a rare inherited blood clotting disorder which affects more than 4, 00,000 people worldwide? In order to cure this disease, Pain Therapeutics has licensed a new technology for treatment of this disorder. It was Stanford University School of Medicine which originally developed this technology and it would be entering the clinic by 2008. Remi Barbier, President and CEO, Pain Therapeutics stated: This licensing is part of our strategy to develop novel drug candidates in hematology/oncology, while maintaining a business model that requires a modest outlay of cash. Within a year the company would be developing a novel drug candidate which would be targeting major mechanism underlying hemophilia. Though the basic research would be undertaken at Stanford Pain Therapeutics would be focusing on the clinical program. Let’s hope that this time we are able to eradicate this disease from this world. Via prnewswire

Source:
http://www.biotechblog.org/rss.xml

B-12 vitamin puzzle solved by MIT biologist

February 5th, 2012

This mystery had troubled researchers for decades but Harvard and MIT researchers have finally been able to join all the pieces together. They have been able to figure out the last link of the synthesis pathway of vitamin B-12. This vitamin makes an immense contribution to the health of human beings. The researchers found out that a single enzyme synthesis the fragment and this outlines a new reaction mechanism which requires cannibalization of another vitamin. Graham Walker, Professor of biology, MIT stated: The work, which has roots in an MIT undergraduate teaching laboratory, completes a piece of our understanding of a process very fundamental to life. Researchers have now come to know that a mutant which has a defective form of enzyme known as BluB results ion B12 not being synthesized. Now a question which still needs to be solved is at to why soil bacteria synthesize B12 at all. Let’s hope the researchers come up with an answer for this question too. Via biologynews

Source:
http://www.biotechblog.org/rss.xml

South Korea again gives a go ahead to use of human eggs in cloning research

February 5th, 2012

South Korea is playing a risky game as it has given the permission for using human eggs in cloning research despite a high level scandal in their country which involved one of their top scientists admitting to his involvement in doctored research work. Hwang Woo-suk was the scientist who had claimed that he had cloned human embryos and extracted stem cells from them but it was found out that all his claims were false. What raised eyes were when eggs required for research were donated by a female scientist in his team and this questioned the ethics of such practice. This shameful incident caused Hwang Woo-suk to resign from his post at the Seoul National University and is now facing trial for misappropriation of government funds. In order to get over the shameful act the government has again given a go ahead to use of human eggs in cloning but this time with an act of caution and under a new set of guidelines has asked that researchers should only use eggs which are to be destroyed after fertility treatments or from other legal ways and a prior license would have to be obtained from the government for undertaking research. It seems this time South Korea wants to take no chances. Via theage

Source:
http://www.biotechblog.org/rss.xml

Ruckus over FDA’s approval to food from cloned animals

February 5th, 2012

The Food and Drug Administration is facing criticism over its recent preliminary approval to food from cloned animals as a consumer group has charged the agency for using flawed analysis. According to the Center for Food Safety, the FDA could not find studies on milk or meat from clones and whether they’re safe and the agency relied on studies done on cloned animals and whether they appeared healthy. Claiming that the conclusions drawn by the FDA was based on ‘scant data from few peer-reviewed studies’, Charles Margulis, a spokesman for Center for Food Safety, said: There isn’t the science to show that these foods are safe. I think the agency was heavily influenced by the biotechnology industry. Though FDA was tight lipped, Val Giddings, a scientist who consults with biotechnology companies, has come forward in FDA’s defence. According to Giddings an exhaustive amount of peer-reviewed data was the base of the conclusion. Giddings said: There’s not a single shred of data to suggest that food derived from clones or their offspring is in any way unsafe. All of what FDA has done here has been completely transparent. The FDA found that food from clones and food from conventional livestock has no virtual difference between and therefore special labels for cloned food would be necessary. Center for Food Safety might be in the process of waging a war against the FDA but Dean Foods Co. of Dallas has already decided to go against the idea of cloned food. Nations biggest milk company has decided it would not sell milk from cloned cows. The company’s decision was influenced by various surveys suggesting the dislike for dairy products from clones by Americans. Source.

Source:
http://www.biotechblog.org/rss.xml

Soluble Omega-3 fats for cosmetics developed by Zymes

February 5th, 2012

A water soluble omega 3 fatty acid has been developed by Zymes using nanotechnology for cosmetic applications. Since Omega 3 has got a dense composition of oil therefore at times it becomes difficult for formulating it with other ingredients. Here nanotechnology comes into picture as it offers increased solubility along with bioavailability and particle size reduction at nanometer level which leads to increased opportunities for companies looking to supplement their products with natural functional ingredients. Ubisol-Aqua from Zymes implements nanotechnology for improving the solubility of drugs and ingredients which are water insoluble and hence it becomes difficult for the human body to absorb it. The company has developed an omega 3fatty acid with 34 nanometers which implies that smaller particles could be absorbed easily into the skin or hair shaft of the user. It is also expected to increase the health benefits to the consumers. Via cosmeticdesign

Source:
http://www.biotechblog.org/rss.xml

Bdelloid rotifers evolving over the past forty million years without sex

February 5th, 2012

We were up till now aware of the fact that sexual reproduction was the only means of bringing life into this world but a group of microscopic organisms seems to have broken this fact. A recent study has found out that since the past forty million years Bdelloid rotifers were evolving without sex. These aquatic animals thrive in wet areas and are asexual. In this case the Bdelloid rotifers produce eggs which are genetic clones of the mother and above all there is no male species, just females out there doing their job. That sounds amazing!! We are all aware of the fact that asexual animals cannot evolve and mutate over a period of time but study of the fossil records of bdelloid rotifers has stated that their existence can be traced back to forty million years. Up till now it was thought that sexual reproduction was important for spitting into divergent species but this has shocked everybody and also left a question to be answered as to how these species have been able to diverge without the addition of any genetic material. Via cbc

Source:
http://www.biotechblog.org/rss.xml

Preserve meats the ‘green way’ using green tea and some wildflower dark honey

February 5th, 2012

Now you can avoid those chemical preservatives used to reduce pathogenic bacteria in meats. Go the ‘green’ way inspite. Extracts from green tea or Jasmine tea do all the magic taking the help of some wildflower dark honey. This scientific non-chemical, organic mixture can reduced Listeria monocytogenes in a turkey breast slice by 10 to 20 percent. Even applied to hot dogs, similar pathogen reductions have been observed. Daniel Fung, the Kansas State University food science professor who supervised the research for the Food Safety Consortium said, Our results indicated that Jasmine tea with honey and green tea with honey had the highest antimicrobial activity. Innovative and impertinent Fung said, We’re thinking of using tea to wash carcasses because of its natural compounds. If you can use tea or honey to wash carcasses instead of lactic acid, you can use a natural compound on the surface of meat.

Source:
http://www.biotechblog.org/rss.xml

Notorious cancer gene may be responsible for tumor growth

February 5th, 2012

A recent study has confirmed that a notorious cancer gene may be the reason for growth of tumor. Research involved the study of a protein called PMR1 which is a major player in the unusual mechanism that cells use for restraining the production of important proteins. Daniel R. Schoenberg, Professor, molecular and cellular biochemistry stated: The link between Src and cancer was discovered 30 years ago, but to this day, we still don’t know its exact role in tumor development. Our data suggest that Src may promote cancer by causing PMR1 to halt production of proteins that normally put the brakes on cell growth – tumor-suppressor proteins, for example, or other growth-regulating proteins The researchers figured out that activation takes place when PMR1 is joined temporarily by an unidentified enzyme and a contact with these enzymes leads to some changes in PMR1 properties and it also binds its targets mRNA. Via biologynews

Source:
http://www.biotechblog.org/rss.xml

Smartgels can avoid surgery for chronic lower back pain patients

February 5th, 2012

University of Manchester scientists have figured out that injections of sponge-like particles could help in avoiding surgery required in case of chronic lower back pain. The researchers have developed tiny gel particles which when injected into the damaged area tend to swell and stiffen. It has been discovered that degenerated animal intervertebral discs having these injected microgels regained their mechanical properties. If this turns out to be successful then patients would be able to gain their mobility after receiving these injections. When dispersed in water the microgel particles turn into smart sponges. It is a low pH fluid which can be injected with the aid a syringe and at physiological pH values it turns to stiff gel. It was developed in response to the need for non surgical method for repairing of intervertebral discs. In the future we might see biodegradable microgels releasing additives for stimulation of regeneration of intervertebral disc tissue. Via biologynews

Source:
http://www.biotechblog.org/rss.xml

Secrecy surrounding genetically engineered grapes field tests can have serious repercussions

February 5th, 2012

UC Davis and Cornell University have the approval for testing genetically engineered grapes in California. In this case no application or environmental assessments were undertaken for the permits and there were just notifications given by the institutes. As far as the field tests are concerned there seems to be a veil of secrecy surrounding them therefore grape growers are not aware regarding the measures which need to be taken for protecting their vineyards from genetic contamination which could dent their image and even cause huge losses if the customers shun genetically engineered products. USDA was even criticized for not paying attention towards the field trials being undertaken and the U.S. Inspector General report said: USDA lacks basic information about the field test sites it approves and is responsible for monitoring, including where and how the crops are being grown, and what becomes of them at the end of the field test. It was only last month when a federal judge ruling stated that USDA cannot give approval for new GE field trials without environmental assessments but this wont be applicable to the grape field tests which have been already given permission. Such secrecy is expected to cause huge problems in the future for GE foods and if proper study and transparency is not ensured then genetically modified food will have a tough time ahead. Via napavalleyregister

Source:
http://www.biotechblog.org/rss.xml

AcrivaUD Reviol Toric T MFM 611 IOL Implantation – VSY Biotechnology – Video

February 3rd, 2012


31-01-2012 07:26

See more here:
AcrivaUD Reviol Toric T MFM 611 IOL Implantation – VSY Biotechnology – Video

'Yellow biotechnology': Using plants to silence insect genes in a high-throughput manner

February 3rd, 2012

ScienceDaily (Feb. 2, 2012) — 'Yellow biotechnology' refers to biotechnology with insects — analogous to the green (plants) and red (animals) biotechnology. Active ingredients or genes in insects are characterized and used for research or application in agriculture and medicine. Scientists at the Max Planck Institute for Chemical Ecology in Jena, Germany, are now using a procedure which brings forward ecological research on insects: They study gene functions in moth larvae by manipulating genes using the RNA interference technology (RNAi). RNAi is induced by feeding larvae with plants that have been treated with viral vectors. This method — called “plant virus based dsRNA producing system” (VDPS) — increases sample throughput compared to the use of genetically transformed plants. 

Natural toxins against herbivores

More than 200,000 insects species are herbivores. They depend on plants for food and have adapted their metabolism accordingly in the course of evolution to render plant defenses, such as the toxins plants produce to fend off herbivores, ineffective. The operating instructions of these detoxification processes are coded in different genes. Insects have evolved an enormous diversity of adaptation mechanisms; they colonize most habitats on this planet — which makes them interesting research objects in ecological studies. Which insect species attack which plants species? Which toxins or signaling substances are involved? Has the insect species adapted to one specific plant species or is it a food generalist? Interesting for agriculture: Which genes allow particular pest insects, such as the pollen beetle Meligethes aeneus or the Western corn rootworm Diabrotica virgifera virgifera, to be so destructive to crop plants? Knowing these detoxification genes and switching them off with the consequence that plant toxins are no longer effective, is currently a research subject in plant breeding. First success stories have already been reported — thanks to the use of RNAi technology.

Scientists at the Max Planck Institute for Chemical Ecology examined a well-known plant toxin: nicotine. Plants of the species Nicotiana attenuata (coyote tobacco) produce nicotine as a defensive substance against herbivores. However, it does not have any toxic effects on their worst enemy: larvae of the tobacco hornworm Manduca sexta. The insect is resistant against this alkaloid; genes that encode nicotine-catabolizing enzymes may be responsible for its resistance. These so called CYP genes are involved in the formation of cytochrome P450 enzymes; the expression of some of these genes is increased as soon as the insect larvae are exposed to nicotine in their food. Ian Baldwin and his team identified the DNA sequences of CYP genes in Manduca sexta and were able to switch off these genes using RNAi technology, but expressed in the plant.

Using plants to silence insect genes

RNA interference (RNAi) is triggered by the production of double-stranded RNA (dsRNA) comprising about 300 base pairs in the cells of tobacco plants. If larvae feed on these plant, the RNA is released in the insect gut. In the experiments, the dsRNA harbored the sequence of the insect gene,CYP6B46, a special cytochrome P450 oxidoreductase specific for Manduca sexta larvae. In a next step, the dsRNA was enzymatically broken down into smaller RNA segments; a special enzyme complex called RISC (RNA-induced silencing complex), which carries several of these RNA segments, specifically binds to the messenger RNA (mRNA) of the CYP6B46 gene and disassembles the mRNA in such a way that the cytochrome P450 enzyme cannot be produced anymore. “We were impressed by the high specificity of these RNAi experiments. The analysis of mRNA transcripts of closely related CYP6 genes revealed that only the CYP6B46 gene was silenced. This means that there was no collateral damage from the procedure: the gene silencing worked on only one targeted gene,” says Ian Baldwin.

The use of additional CYP RNAi probes revealed further interesting results: Young caterpillars which had ingested dsRNA of the CYP4M3 gene gained significantly less weight within 14 days in comparison to larvae reared on control plants — very likely a consequence of the nicotine and its toxic effect which had been restored by switching off the CYP gene. The RNAi experiments had been conducted using plant viral vectors. Unlike genetically transformed tobacco plants in which CYP dsRNA is produced constitutively, the virus vector-based technique provides dsRNA transiently produced in wildtype tobacco plants. Both methods worked well but the “plant virus-based dsRNA producing system” (VDPS) allows for a throughput of RNAi samples that is four times faster. Many unknown functions of different insect genes involved in the adaptation of insects to their environment can now be analyzed using the VDPS technique.

However, it is still unclear how the individual steps in the RNAi mechanism — from producing dsRNA in the plant cell via their uptake in the insect gut to the silencing of the detoxification genes — are accomplished to induce a maximum effect. One experiment provided some interesting information: If the enzymatic step which dices dsRNA into small fragments is inhibited in the experimental plants, the amount of transcripts of the detoxification gene was reduced even further. Therefore the plant mediated RNAi procedure may be more effective, if the caterpillars ingest complete dsRNA instead of smaller diced RNA segments.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Max Planck Institute for Chemical Ecology.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Pavan Kumar, Sagar Subhash Pandit, Ian T. Baldwin. Tobacco Rattle Virus Vector: A Rapid and Transient Means of Silencing Manduca sexta Genes by Plant Mediated RNA Interference. PLoS ONE, 2012; 7 (2): e31347 DOI: 10.1371/journal.pone.0031347

Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.

More here:
'Yellow biotechnology': Using plants to silence insect genes in a high-throughput manner

Research and Markets: International Directory of Biotechnology Companies 2012: a must-have for anyone who needs to …

February 3rd, 2012

Research and Markets has announced the addition of the “International Directory of Biotechnology Companies 20

See the original post:
Research and Markets: International Directory of Biotechnology Companies 2012: a must-have for anyone who needs to …

RBCC: Biotech Industry on Major Upswing in 2012

February 3rd, 2012

All signs point to emerging biotech company Rainbow Coral Corp. finding its feet in biotechnology at exactly the right time: The biotech industry is off to a great sta

Follow this link:
RBCC: Biotech Industry on Major Upswing in 2012

Biotechnology Workshop for School Students at Dr. MGR University – Video

February 1st, 2012


26-01-2012 23:29 Biotechnology Workshop for School Students at Dr. MGR University

Go here to see the original:
Biotechnology Workshop for School Students at Dr. MGR University – Video

Andalusian Centre for Nanomedicine and Biotechnology, BIONAND – Video

January 31st, 2012


25-01-2012 12:00 The Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, is a mixed centre with stakes held by the Regional Ministry of Innovation, Science and Enterprise, the Regional Ministry of Health and the University of Malaga with the purpose to promote and encourage the development of an andalusian centre for excellence research in Nanomedicine.

Read the original:
Andalusian Centre for Nanomedicine and Biotechnology, BIONAND – Video

Biotech Sector on the Upswing — Dendreon and ADVENTRX Pharmaceuticals Looking Strong

January 31st, 2012

NEW YORK, NY–(Marketwire -01/31/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN – News) and ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX – News). Access to the full company reports can be found at:

www.fivestarequities.com/DNDN
www.fivestarequities.com/ANX

Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

ADVENTRX's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. In December ADVENTRX met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.fivestarequities.com/disclaimer

Originally posted here:
Biotech Sector on the Upswing — Dendreon and ADVENTRX Pharmaceuticals Looking Strong

14th Annual BIO CEO & Investor Conference to Highlight 2012 Investment Outlook, New Business Models and Key …

January 31st, 2012

WASHINGTON–(BUSINESS WIRE)– The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference. Experts chosen to speak on these panels represent leading clinical practitioners, investment professionals, industry analysts and senior biotechnology executives. The conference, to be held February 13-14, 2012 in New York City, is the largest independent investor conference focused on established and publicly-traded biotechnology companies.

“Marked by several M&A transactions, development deals and FDA approvals, 2012 has already been an eventful year in biotech. This year’s program will delve into some of the therapeutic and business catalysts driving positive activity in the biopharma industry,” said Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development at BIO. “The regulatory and financial challenges faced by our industry highlight the need for an independent forum where top industry executives and investment professionals can convene to discuss innovative deal structures and financing mechanisms.”

The BIO CEO & Investor Conference plenary sessions will cover the economic and business issues facing the biotech industry. The Business Roundtables will focus on biotech drug launches, unique business models and licensing and deal making. Therapeutic Workshops will address topics such as oncology, companion diagnostics, neurological and cardiovascular diseases.

Plenary sessions include:
Opening Plenary: Picks and Pans – The Buy-Side View for 2012
Monday, February 13th, 12:00 pm – 12:55 pm

Moderator: Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Panelists:

Alexander J. Denner, PhD, (former) Managing Director, Icahn Associates Rajiv Kaul, Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity Greg Martinez, Portfolio Manager, Harbor Watch Capital Management LLC

Luncheon Plenary: Business Development: Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation
Tuesday, February 14th, 12:00 pm – 12:55 pm

Moderator: Ben Bonifant, Senior Vice President and Practice Area Leader, Campbell Alliance
Panelists:

Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, RPh, Managing Director, Healthcare Investment Banking, ROTH Capital Partners Barbara Yanni, JD, LLM, CLP, Vice President and Chief Licensing Officer, Merck & Co

Closing Plenary: Inside the FDA
Tuesday, February 14th, 4:00 pm – 5:00 pm

Moderator: James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO)
Panelists:

Paul J. Hastings, President & CEO, OncoMed Pharmaceuticals, Inc. Jonathan S. Leff, Managing Director, Healthcare, Warburg Pincus, LLC Richard Pops, Chairman & CEO, Alkermes plc Stephen P. Spielberg, MD, PhD, Deputy Commissioner for Medical Products & Tobacco, FDA

Business Roundtables include:
Business Roundtable: Corporate Strategy
Walking the Line – Finding a Happy Medium between Management and Shareholders
Monday, February 13th, 9:00 am – 9:55 am

Moderator: Annette Grimaldi, Managing Director, BMO Capital Markets
Panelists:

Tillman U. Gerngross PhD, Co-Founder & CEO, Adimab, Inc. Peter Kolchinsky, PhD, Portfolio Manager, RA Capital Management Steven Tregay, PhD, Founder, President & CEO, Forma Therapeutics Steve Worland, PhD, President & CEO (former), Anadys Pharmaceuticals, Inc.

Business Roundtable: Finance
Healthy Alternatives: Non-Dilutive Financing Mechanisms that Sustain Companies
Monday, February 13th, 3:00 pm – 3:55 pm

Moderator: Dean Colucci, President & General Counsel, MLV & Co
Panelists:

Luke M. Beshar, CPA, Sr. Vice President & Chief Financial Officer, NPS Pharmaceuticals Inc. John R. Leone, Partner, Healthcare, Paul Capital Ivana Magov?evi?-Liebisch, PhD, JD. Executive Vice President and Chief Business Officer Russell H. Plumb, MBA, President & Chief Executive Officer, Inhibitex Inc.

Business Roundtable: Corporate Development
Countdown to Launch – Getting it Right the First Time
Tuesday, February 14th, 9:00 am – 9:55 am

Moderator: William Ho, Public Investment Director, New Leaf Venture Partners
Panelists:

Pedro Lichtinger, President & CEO, Optimer Pharmaceuticals Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma, Inc.

Therapeutic Workshops include:
Therapeutic Workshop: Oncology
Secrets of Oncology Success – Lessons and Trends in Phase II Clinical Trial Outcomes
Monday, February 13th, 10:30 am – 11:25 am

Moderator: Michael G. King, Jr., Managing Director, Rodman & Renshaw, LLC
Panelists:

Mohammad Azab, MD, M Sc, MBA, Chief Medical Officer, Astex Pharmaceuticals Inc. Konstantin H. Dragnev, MD, Hematology/Oncology, Dartmouth-Hitchcock Medical Center Michael M. Morrissey, PhD, President & Chief Executive Officer, Exelixis, Inc. Robert F. Ozols, MD, PhD, Senior Vice President, Fox Chase Cancer Center

Therapeutic Workshop: Neurology
Neurology: “Alz” Well That Ends Well – Settling the Beta – Amyloid Debate
Monday, February 13th, 1:30 pm – 2:25 pm

Moderator: Joshua Schimmer, MD, Managing Director, Biotechnology, Leerink Swann, LLC
Panelists:

Ted T. Ashburn, MD, PhD, Senior Director, Corporate Development, Genzyme Corp Michael Gold, MS, MD, Vice President, Clinical Development & Chief Medical Officer, Allon Therapeutics Inc. Marc L. Gordon, MD, Chief of Neurology, Associate Professor of Neurology and Psychiatry, Zucker Hillside Hospital, Hofstra North Shore-LIJ School of Medicine Hyoung-Gon Lee, PhD, Assistant Professor, Case Western University

Therapeutic Workshop: Diagnostics
Drugs Need Friends Too – Companion Diagnostics and Drug Development
Tuesday, February 14th, 10:30 am – 11:25 am

Moderator: Steve Brozak, President, WBB Securities LLC
Panelists:

Thomas Davis, MD, Senior Vice President & Chief Medical Officer, Celldex Therapeutics, Inc. Joanna C. Horobin, MD, President & CEO, Syndax Pharmaceuticals, Inc. Patrick J. Mahaffy, President and Chief Executive Officer, Clovis Oncology

Therapeutic Workshop: Cardiology
Shot to the Heart – The Race to Conquer Dyslipidemia / Hypercholesterolemia
Tuesday, February 14th, 1:15 pm – 2:10 pm

Moderator: Michael J. Haas, Senior Writer, BioCentury Publications, Inc.
Panelists:

Per Bengtsson, MD, PhD, President & CEO, Kara Bio AB Ram Y. Gordon, MD, Clinical Cardiologist, University of Pennsylvania Mark Sumeray, MD, MS, FRCS, Chief Medical Officer, Aegerion Pharmaceuticals, Inc.

To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here. Registration is complimentary for qualified investors and credential members of the media.

The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. Investors attend to network with top biotechnology executives, evaluate fresh investment opportunities, attend candid panel discussions and get an overview of the industry and key issues affecting investments.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The bank sponsors include: BMO Capital Market, Lazard, Leerink Swann, Stifel Nicolaus Weisel, Rodman & Renshaw, LLC and Roth Capital Partners.

Upcoming BIO Events

BIO Asia International Conference
January 31 – February 1, 2012
Osaka, Japan

BIO CEO & Investor Conference
February 13-14, 2012
New York, NY

BIO IP Counsels Committee Conference
April 16 – 18, 2012
Austin, TX

World Congress on Industrial Biotechnology & Bioprocessing
April 29-May 2, 2012
Orlando, FL

2012 BIO International Convention
June 18-21, 2012
Boston, MA

BIO Business Forum
June 18 – 21, 2012
Boston, MA

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, a multiblog platform and monthly newsletter that aims to create an online biotech community where the the industry can connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

Follow this link:
14th Annual BIO CEO & Investor Conference to Highlight 2012 Investment Outlook, New Business Models and Key …







Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Web Design by PlatinumShore.com & Web Hosting by TradeWebHosting.com